Hyperion DeFi (NASDAQ:HYPD – Get Free Report) and Sentage (NASDAQ:SNTG – Get Free Report) are both small-cap finance companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.
Insider and Institutional Ownership
25.8% of Hyperion DeFi shares are held by institutional investors. Comparatively, 0.1% of Sentage shares are held by institutional investors. 7.5% of Hyperion DeFi shares are held by insiders. Comparatively, 62.4% of Sentage shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of current ratings and recommmendations for Hyperion DeFi and Sentage, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Hyperion DeFi | 2 | 0 | 2 | 0 | 2.00 |
| Sentage | 1 | 0 | 0 | 0 | 1.00 |
Earnings and Valuation
This table compares Hyperion DeFi and Sentage”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Hyperion DeFi | $810,000.00 | 63.31 | -$45.31 million | ($6.53) | -0.51 |
| Sentage | $70,000.00 | 68.24 | -$2.28 million | N/A | N/A |
Sentage has lower revenue, but higher earnings than Hyperion DeFi.
Profitability
This table compares Hyperion DeFi and Sentage’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Hyperion DeFi | 416.56% | -11.62% | -9.96% |
| Sentage | N/A | N/A | N/A |
Risk and Volatility
Hyperion DeFi has a beta of 2.53, suggesting that its share price is 153% more volatile than the S&P 500. Comparatively, Sentage has a beta of 2.43, suggesting that its share price is 143% more volatile than the S&P 500.
Summary
Hyperion DeFi beats Sentage on 7 of the 12 factors compared between the two stocks.
About Hyperion DeFi
Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.
About Sentage
Sentage Holdings Inc. provides a range of financial services. The company offers consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China. It also provides consultancy and information technology support services. Sentage Holdings Inc. was incorporated in 2019 and is headquartered in Shanghai, the People's Republic of China.
Receive News & Ratings for Hyperion DeFi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hyperion DeFi and related companies with MarketBeat.com's FREE daily email newsletter.
